GI CANCERS

Tara Seery, MD, explains the next steps for the QUILT 88 study looking at a novel combination of therapies for patients with metastatic pancreatic cancer.

In the phase 3 TIGeR-PaC study, intra-arterial administration of gemcitabine demonstrated positive progression-free and overall survival outcomes in patients with locally advanced pancreatic cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, and participants discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab.

The FDA plans to conduct a speedy review of an approval application for zolbetuximab in first-line locally advanced, unresectable, or metastatic HER2-negative, claudin18.2-positive gastric or gastroesophageal junction adenocarcinoma.

Data from an early access program and the eNRGy trial evaluating zenocutuzumab have led the FDA to grant the agent breakthrough designation for patients with NRG1 fusion-positive pancreatic cancer.

The phase 2b VIRAGE study will investigate the safety and efficacy of VCN-01 plus standard chemotherapy in patients with first-line pancreatic ductal adenocarcinoma.

Durable responses in patients with metastatic pancreatic ductal adenocarcinoma treated with mitazalimab plus chemotherapy have led to discussions with regulatory authorities.

Druggable targets for patients with gastrointestinal cancers were discussed during the 20th Annual Meeting of the International Society of Gastrointestinal Oncology.

According to phase 3 study results, the combination of pembrolizumab and chemotherapy can induce high rates of response in patients with gastroesophageal junction adenocarcinoma while maintaining safety.

Data from the phase 3 NAPOLI 3 trial have led the FDA to accept a supplemental new drug application for NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma

A regular review of an FDA approval application is underway for the combination of pembrolizumab and standard chemotherapy for the treatment of advanced biliary tract cancer.

The same high cure rates achieved with preoperative chemoradiation can be achieved with preoperative FOLFOX, according to Deb Schrag, MD, FASCO, MPH.

Results from the phase 2b HERIZON-BTC-01 trial presented at ASCO reveal positive efficacy and safety in patient with advanced biliary tract cancer who received zanidatamab.

ACTION-1 is investigating RYZ101 versus standard-of-care therapy in patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors after 177Lu-SSA therapy.

The claudin 18.2 antibody-drug conjugate ATG-022 is being investigated in a phase 1 study as a potential treatment for advanced or metastatic solid tumors.

Mitazalimab has received an orphan drug designation from the FDA and is currently being investigated in the OPTIMIZE-1 trial in combination with modified FOLFIRINOX for the treatment of patients with pancreatic cancer.

According to interim phase 2 results, GEN-001 in combination with avelumab has a significant objective response rate in patients with gastric and gastroesophageal junction adenocarcinoma.

Rucosopasem manganese is being investigated in the phase 1/2 GRECO-1 and phase 2b GRECO-2 trials in combination with stereotactic body radiation therapy for the treatment of patients withlj non–small cell lung cancer and pancreatic cancer.

The phase 3 RATIONALE-306 study displayed encouraging survival and safety data among patients with advanced or metastatic esophageal squamous cell carcinoma who were treated with tislelizumab and chemotherapy.

NALIRIFOX improved overall survival and progression-free survival in patients with metastatic pancreatic ductal adenocarcinoma.

Development of PYX-201 in advanced solid tumors is underway, and the drug has grabbed the FDA's attend with a phase 1 study in pancreatic cancer.

An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.

The new DNA methylation-based PDACatch assay has received a breakthrough device designation from the FDA to detect patients at high-risk for pancreatic adenocarcinoma.

In an interview with Targeted Oncology, Ken Kato, MD, PhD, discussed background and findings from the phase 3 CheckMate 648 trial among patients with esophageal squamous cell carcinoma.